Navigation Links
Half-million-dollar DNA sequencer to boost genetic science research at UH
Date:10/17/2007

HOUSTON, Oct. 17, 2007 Not too long ago, deconstructing and analyzing DNA codes took scientists several years and enough chemistry and computer hardware to fill the entire floor of a building. Now, a genetic sequencer the size of a washing machine can do the work in a couple of days.

Thanks to a $750,000 grant from the Cullen Foundation awarded to the University of Houstons Institute for Molecular Design (IMD), researchers will be among the first in the region to use this cutting-edge device. Headed by B. Montgomery Pettitt, Hugh Roy and Lillie Cranz Cullen Distinguished Professor in Chemistry, professor of computer science, physics, biology and biochemistry, and associate dean of research for the UH College of Natural Sciences and Mathematics, the IMD also recently received a $500,000 grant from the M.D. Anderson Foundation for construction and build-out costs associated with the Science & Engineering Research and Classroom Complex (SERCC).

A complex of three main structures, SERCC includes a five-story laboratory building with more than 150,000 square feet that will accommodate an estimated 40 research labs designed to support interaction. Among the buildings features are labs opening up to other labs with few walls to isolate them, as well as a dedicated, full-service clean room with a non-vibration floor, static-free environment and special air filters to remove virtually all dust particles. These new capabilities will allow for more collaborative, cross-disciplinary research among UH faculty in addition to benefiting local academic and industry partners who participate in the universitys research efforts.

Set to arrive by December, the $500,000 DNA sequencer made possible by the Cullen Foundation grant will help make UH a major player in genetic science by allowing the analysis not only of whole organisms but also of sampling with many organisms mixed together.

An organisms genome can contain the equivalent
'/>"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Spirulina may be the next immune boost on the block
2. New drug helps boost cancer treatment
3. A boost to quit smoking
4. Hepatitis G May Boost HIV Survival
5. Drug Combinations May Boost Stroke Risk
6. Myth of female impotence created to boost sales
7. Reduced Fatigue Boosts Mental Health
8. Therapy Boosts Chemotherapy Effects
9. Need for Hepatitis Booster Questioned
10. Vasopressin Found To Boost Survival In Sudden Cardiac arrest
11. Exercising To Music Found To Boost Brain Power
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10How to reduce hospital stays and increase patient satisfaction 58689 1How to reduce hospital stays and increase patient satisfaction 58689 2Natural killer cells keep immune system in balance 10226 1Natural killer cells keep immune system in balance 10226 2Ardi displaces Lucy as oldest hominid skeleton 10222 1Ardi displaces Lucy as oldest hominid skeleton 10222 2Ardi displaces Lucy as oldest hominid skeleton 10222 3Ardi displaces Lucy as oldest hominid skeleton 10222 4Ardi displaces Lucy as oldest hominid skeleton 10222 5